Except for tezepelumab (anti-TSLP), these biologics are approved for asthma with specific biomarker elevations relevant to these pathways: sensitization to a perennial aeroallergen (anti-IgE), elevated AEC [anti-IL-5, anti-IL-5 receptor (IL-5R), anti-IL-4Rα], and increased FeNO (anti-IL-4Rα). This evidence concerns the gene IL5 and asthma.